Evaluation of the efficacy of low‐dose liraglutide in weight control among Taiwanese non‐diabetes patients

Aims/Introduction Obesity and metabolic syndrome are well‐known to be associated with multiple chronic diseases. Currently, high‐dose liraglutide has been used for weight control in non‐diabetic patients. Considering incretin‐based therapy is more effective in Asian populations, the effect of low‐dose liraglutide in weight control among these non‐diabetic groups has not been well evaluated. Our study aimed to evaluate the efficacy of low‐dose liraglutide in weight control among Taiwan patients. Materials and Methods From July 2017 to December 2018, 46 non‐diabetic patients with metabolic syndrome were included. They had received low‐dose liraglutide at 0.6 or 1.2 mg per day for weight reduction for 12 weeks. After then, changes in bodyweight, waist and metabolic factors were examined. Overt bodyweight reduction was defined as a decrease of >5% within 12 weeks. Results With 12 weeks of medication use, both groups showed statistical weight reduction. Higher doses of liraglutide had better efficacy, and 44.4% of patients in the liraglutide 1.2 mg group reached overt weight reduction, whereas just 32.1% in the 0.6 mg group had achieved this. Young age was found to be a predictor factor for a positive finding (odds ratio 0.941, P  = 0.037). Early responders with decreased bodyweight of >4.2% within the first 4 weeks indicated a better chance to achieve measurable weight reduction. Conclusions Low‐dose liraglutide still has high efficacy in weight reduction in Taiwanese people, especially for those of younger age.